Post‐genomic vaccine development

Serruto, Davide; Rappuoli, Rino

doi:10.1016/j.febslet.2006.04.084

Cited by 126 publications

(94 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although successful in many cases, these approaches have failed to provide vaccines against pathogens that did not have obvious immunodominant protective antigens [12]. With the advent of whole-genome sequencing and advances in bioinformatics, the vaccinology field has radically changed, providing the opportunity for developing novel and improved vaccines.…”

Section: (E) From Genomes To Reverse Vaccinologymentioning

confidence: 99%

Delivering vaccines to the people who need them most

Barocchi

Rappuoli

2015

Phil. Trans. R. Soc. B

Self Cite

View full text Add to dashboard Cite

Thanks to the Global Alliance for Vaccines and Immunization (GAVI), the Vaccine Fund and the Bill & Melinda Gates Foundation, the global health community has made enormous progress in providing already existing vaccines to developing countries. However, there still exists a gap to develop vaccines for which there is no market in the Western world, owing to low economic incentives for the private sector to justify the investments necessary for vaccine development. In many cases, industry has the technologies, but lacks the impetus to direct resources to develop these vaccine products. The present emergency with the Ebola vaccine provides us an excellent example where a vaccine was feasible several years ago, but the global health community waited for a humanitarian disaster to direct efforts and resources to develop this vaccine. In the beginning of 2015, the first large-scale trials of two experimental vaccines against Ebola virus disease have begun in West Africa. During the past few years, several institutions have dedicated efforts to the development of vaccines against diseases present only in low-income countries. These include the International Vaccine Institute, the Novartis Vaccines Institute for Global Health, the Hilleman Institute, the Sabin Vaccine Institute and the Infectious Disease Research Institute. Nevertheless, solving this problem requires a more significant global effort than that currently invested. These efforts include a clear policy, global coordination of funds dedicated to the development of neglected disease and an agreement on regulatory strategies and incentives for the private sector.

show abstract

Section: (E) From Genomes To Reverse Vaccinologymentioning

confidence: 99%

Delivering vaccines to the people who need them most

Barocchi

Rappuoli

2015

Phil. Trans. R. Soc. B

Self Cite

View full text Add to dashboard Cite

show abstract

“…Reverse vaccinology uses bioinformatics in the initial steps to identify potential antigens, which are consequently examined for their effectiveness and toxicity. The use of algorithm for prediction of subcellular location improved the power of identifying potential vaccine candidates (Serruto and Rappuoli, 2006). Subsequently, developments have been proposed to reverse vaccinology by suggesting the use of additional algorithms to find probability of being an adhesin, of topology (transmembrane domains) and to find similarity with host protein (Vivona et al, 2006).…”

Section: Malaria Vaccine Researchmentioning

confidence: 99%

Genome Based Vaccines Against Parasites

Shahein¹,

Abouelella²

2011

Molecular Cloning - Selected Applications in Medicine and Biology

View full text Add to dashboard Cite

“…Structural biology is increasingly being applied to vaccine development (structural vaccinology), focusing on determining and understanding the structural basis of immunodominant and immunosilent antigens, to enable the rational design of peptide mimetics of bactericidal epitopes (95,96). The explosion of genome and proteome data, as well as improved protein expression, purification, and structural determination technologies, has led to the rapid development of the field of structural vaccinology (97).…”

Section: Structural Vaccinology: the Next Generation Of Epitope Mappimentioning

confidence: 99%

Vaccinology in the genome era

Rinaudo¹,

Telford²,

Rappuoli³

et al. 2009

J. Clin. Invest.

Self Cite

144

118

View full text Add to dashboard Cite

Vaccination has played a significant role in controlling and eliminating life-threatening infectious diseases throughout the world, and yet currently licensed vaccines represent only the tip of the iceberg in terms of controlling human pathogens. However, as we discuss in this Review, the arrival of the genome era has revolutionized vaccine development and catalyzed a shift from conventional culture-based approaches to genome-based vaccinology. The availability of complete bacterial genomes has led to the development and application of high-throughput analyses that enable rapid targeted identification of novel vaccine antigens. Furthermore, structural vaccinology is emerging as a powerful tool for the rational design or modification of vaccine antigens to improve their immunogenicity and safety.

show abstract

Post‐genomic vaccine development

Cited by 126 publications

References 53 publications

Delivering vaccines to the people who need them most

Delivering vaccines to the people who need them most

Genome Based Vaccines Against Parasites

Vaccinology in the genome era

Contact Info

Product

Resources

About